The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discourages competition and makes it difficult to achieve transparency, affordability, and timely access for patients.
Menendez criticizes the lack of oversight in the PBM market.
Share
More from Bob Menendez
On August 21, New Jersey lost one of the greatest champions in our State's history. Bill Pascrell was more than just a Member of Congress. He was a friend, a mentor, and someone who was loved and admired by many, myself included. Bill was…
More than 700,000 New Jerseyans sent me here to be their voice in Congress and to address the challenges they face each and every day. Many of those constituents have sent me messages advocating for what is most important to them…
In recent weeks, the Trump administration and House Republicans have set their sights on the Federal judiciary, calling for unprecedented changes to our courts, attacking the character of dedicated Federal judges, and attempting to…
Other voices in this conversation
